Small molecule inhibition of cAMP response element binding protein in human acute myeloid leukemia cells

B. Mitton, H. D. Chae, K. Hsu, R. Dutta, G. Aldana-Masangkay, R. Ferrari, K. Davis, B. C. Tiu, A. Kaul, N. Lacayo, G. Dahl, F. Xie, B. X. Li, M. R. Breese, E. M. Landaw, G. Nolan, M. Pellegrini, S. Romanov, X. Xiao, K. M. Sakamoto

Research output: Contribution to journalArticlepeer-review

21 Scopus citations

Abstract

The transcription factor CREB (cAMP Response-Element Binding Protein) is overexpressed in the majority of acute myeloid leukemia (AML) patients, and this is associated with a worse prognosis. Previous work revealed that CREB overexpression augmented AML cell growth, while CREB knockdown disrupted key AML cell functions in vitro. In contrast, CREB knockdown had no effect on long-term hematopoietic stem cell activity in mouse transduction/transplantation assays. Together, these studies position CREB as a promising drug target for AML. To test this concept, a small molecule inhibitor of CREB, XX-650-23, was developed. This molecule blocks a critical interaction between CREB and its required co-activator CBP (CREB Binding Protein), leading to disruption of CREB-driven gene expression. Inhibition of CBP-CREB interaction induced apoptosis and cell-cycle arrest in AML cells, and prolonged survival in vivo in mice injected with human AML cells. XX-650-23 had little toxicity on normal human hematopoietic cells and tissues in mice. To understand the mechanism of XX-650-23, we performed RNA-seq, ChIP-seq and Cytometry Time of Flight with human AML cells. Our results demonstrate that small molecule inhibition of CBP-CREB interaction mostly affects apoptotic, cell-cycle and survival pathways, which may represent a novel approach for AML therapy.

Original languageEnglish (US)
Pages (from-to)2302-2311
Number of pages10
JournalLeukemia
Volume30
Issue number12
DOIs
StatePublished - Dec 1 2016

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Small molecule inhibition of cAMP response element binding protein in human acute myeloid leukemia cells'. Together they form a unique fingerprint.

Cite this